

# NEUROLOGY

## **JUVENILE-ONSET ALPERS SYNDROME: INTERPRETING MRI FINDINGS**

N.A. Visser, K.P.J. Braun, W.M. van den Bergh, F.S.S. Leijten, C.R.B. Willems, L.

Ramos, B.J.C. van den Bosch, H.J.M. Smeets and J.H.J. Wokke

*Neurology* 2010;74;1231-1233

DOI: 10.1212/WNL.0b013e3181d90005

**This information is current as of May 7, 2010**

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://www.neurology.org/cgi/content/full/74/15/1231>

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2010 by AAN Enterprises, Inc. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.



N.A. Visser, MD  
K.P.J. Braun, MD, PhD  
W.M. van den Bergh,  
MD, PhD  
F.S.S. Leijten, MD, PhD  
C.R.B. Willems, MD  
L. Ramos, MD  
B.J.C. van den Bosch,  
PhD  
H.J.M. Smeets, PhD  
J.H.J. Wokke, MD,  
PhD

## JUVENILE-ONSET ALPERS SYNDROME: INTERPRETING MRI FINDINGS


A previously healthy 20-year-old woman was admitted to the department of neurology of our hospital after 2 generalized tonic-clonic seizures in the preceding 2 weeks. Since the first seizure, she had been seeing bright spots. Neurologic examination at admission was normal. EEG showed slowed background activity and continuous epileptic activity in the left occipital lobe. MRI revealed asymmetric but bilateral areas of increased signal intensity in the occipital cortex, most prominent in the left hemisphere (figure, A). During the following weeks, symptoms expanded, as she developed epilepsy partialis continua of her right arm and leg. Repeat brain MRI showed increase and extension of the occipital lesions, now including hyperintensity of the pulvinar region in the left thalamus (figure, B). We considered a diagnosis of juvenile-onset Alpers syndrome, mitochondrial encephalopathy with lactate acidosis and stroke-like episodes, cerebral vasculitis, or Rasmussen encephalitis. Urgent DNA sequencing of all protein encoding exons and at least 40 nucleotides of the flanking introns of the *POLG1* gene, the gene encoding the mitochondrial DNA (mtDNA) polymerase  $\gamma$ , confirmed a homozygous c.1399G>A mutation (p.A467T) as the only mutation or variant present in this gene. The family history was negative for disorders possibly related to *POLG1* mutations. Despite treatment with several combinations of antiepileptic drugs, avoiding valproic acid, she developed a generalized status epilepticus and was admitted to the ICU. Eight weeks after the initial symptoms, she died of refractory status epilepticus with renal failure.

**Discussion.** In 2008, a similar phenotype of *POLG1* mutations has been reported, referred to as juvenile-onset Alpers syndrome.<sup>1</sup> Features are the combination of refractory epilepsy and visual symptoms in a previously healthy adolescent. In contrast, typical Alpers (-Huttenlocher) syndrome, also a *POLG1* mutation phenotype, usually presents in early childhood with the classic triad of developmental delay, intractable seizures, and liver failure.<sup>2</sup>

*POLG1* encodes the catalytic subunit of mtDNA polymerase  $\gamma$ , which is the only polymerase involved in mtDNA replication.<sup>3,4</sup> *POLG1* mutations have been identified in a variety of diseases, ranging from progressive external ophthalmoplegia to Alpers syndrome.<sup>4,5</sup> Inheritance is mostly autosomal recessive, although autosomal dominant transmission and sporadic mutations have been described.<sup>3</sup> The most common *POLG1* mutation is p.A467T, with a human gene frequency of 0.2%–0.6% in certain European populations; this mutation can cause both mild and severe phenotypes (<http://tools.niehs.nih.gov/polg/>).<sup>3–5</sup>

Our case is exceptional with respect to the rapid progression of the disease, which is highly unexpected in patients with a homozygous p.A467T mutation. Previously, compound heterozygotes with a p.A467T mutation showed a shorter survival compared to patients with a homozygous p.A467T mutation.<sup>3</sup> A series of 19 patients with 3 different *POLG1* mutation genotypes, one of which was the homozygous p.A467T mutation, had an overall survival time of 8 years after onset of epilepsy, but individual survival times were not reported.<sup>1</sup> As other variants in *POLG1* were excluded, a possible explanation of the severe phenotype of this patient could be a concurrent mutation in the mtDNA or in one of the many genes involved in mtDNA maintenance, affecting either the replisome or nucleotide pools. However, so far no solid evidence exists for digenic inheritance due to a combined effect of 2 mutations in different genes on the function of the mtDNA replication system and it may also be difficult to prove causality in a single case.

The magnetic resonance abnormalities in our patient are characteristic of the previously described occipital lobe epilepsy phenotype within the spectrum of *POLG1* mutation syndromes.<sup>1</sup> Progressive occipital and thalamic magnetic resonance lesions, as well as increased signal intensities in the cerebellum, have been reported in both typical and juvenile-onset Alpers phenotype.<sup>1,6</sup> The increased cortical signal intensity on diffusion-weighted imaging with areas of decreased apparent diffusion coefficient might be mistaken for ischemia. The apparent diffusion coefficient evolution, however, suggests a combination of both cytotoxic injury and vasogenic edema. Whether



(A) Above: (T2-FLAIR images at admission) hyperintense cortical lesion in the left occipital lobe (right); below: (T2-FLAIR image at admission) hyperintense cortical lesion in the right occipital lobe (left) and (diffusion-weighted MRI at admission) hyperintensity corresponding to left occipital lesion on FLAIR image (right). (B) Above: (T2-FLAIR images after disease progression) increase of occipital lesion and new thalamic lesion (left); below: (diffusion-weighted MRI after disease progression) clearly revealing thalamic and extensive left cortical occipital lesions (left), (corresponding apparent diffusion coefficient map) demonstrates mixed diffusion characteristics of the occipital lesion with areas of decreased and increased cortical diffusion (right). FLAIR = fluid-attenuated inversion recovery.

these cortical and thalamic diffusion changes are specific for mitochondrial dysfunction, or merely reflect the consequences of long-lasting and intractable status epilepticus, remains unclear. Previous studies have demonstrated magnetic resonance lesions in the pulvinar region of the thalamus in patients with partial status epilepticus arising from the posterior quadrants of the brain, probably reflecting the extent of thalamocortical connections within the epileptic circuitry.<sup>7</sup>

The diagnosis of juvenile-onset Alpers syndrome should be considered in patients with (partial) status epilepticus of unknown origin and occipital symptoms or lesions on MRI. Early recognition of this syndrome has important consequences; valproic acid is contraindicated in patients with a (suspected) *POLG1* mutation phenotype, because of severe hepatotoxicity.<sup>3,5</sup> Urgent DNA analysis can confirm the diagnosis and genetic counseling can be offered.

From the Department of Neurology (N.A.V., F.S.S.L., C.R.B.W., J.H.J.W.) and Department of Child Neurology (K.P.J.B.), Rudolf Magnus Institute of Neuroscience, and Department of Radiology

(L.R.), University Medical Center Utrecht, Utrecht, the Netherlands; Department of Intensive Care (W.M.v.d.B.), Academic Medical Center, Amsterdam, the Netherlands; and Department of Clinical Genetics (B.J.C.v.d.B., H.J.M.S.), Maastricht University Medical Center, Maastricht, the Netherlands.

Disclosure: Dr. Visser reports no disclosures. Dr. Braun serves on the editorial board of the Dutch Journal of Neurology and Neurosurgery (Tijdschrift voor Neurologie en Neurochirurgie) and receives research support from the Dutch National Epilepsy Fund. Dr. van den Bergh, Dr. Leijten, Dr. Willems, Dr. Ramos, and Dr. van den Bosch report no disclosures. Dr. Smeets receives research support from the European Union, The Dutch Organization for Scientific Research (NWO), and the Netherlands Diabetes Fund. Dr. Wokke serves on the editorial boards of The Lancet Neurology and Neuromuscular Disorders.

Received July 19, 2009. Accepted in final form November 30, 2009. Address correspondence and reprint requests to Dr. N.A. Visser, Department of Neurology, University Medical Center Utrecht, P.O. Box 85500, 3508 GA Utrecht, the Netherlands; n.a.visser-3@umcutrecht.nl

Copyright © 2010 by AAN Enterprises, Inc.

#### ACKNOWLEDGMENT

The authors thank the family of this patient for their permission to publish this article.

- Engelsen BA, Tzoulis C, Karlsen B, et al. *POLG1* mutations cause a syndromic epilepsy with occipital lobe predilection. *Brain* 2008;131:818–828.
- Harding BN. Progressive neuronal degeneration of childhood with liver disease (Alpers-Huttenlocher syndrome): a personal review. *J Child Neurol* 1990;5:273–287.
- Hudson G, Chinnery PF. Mitochondrial DNA polymerase-gamma and human disease. *Hum Mol Genet* 2006;15:R244–R252.
- Copeland WC. Inherited mitochondrial diseases of DNA replication. *Annu Rev Med* 2008;59:131–146.
- Naviaux RK, Nguyen KV. *POLG* mutations associated with Alpers' syndrome and mitochondrial DNA depletion. *Ann Neurol* 2004;55:706–712.
- Wolf NI, Rahman S, Schmitt B, et al. Status epilepticus in children with Alpers' disease caused by *POLG1* mutations: EEG and MRI features. *Epilepsia* 2008;50:1596–1607.
- Katramados AM, Burdette D, Patel SC, Schultz LR, Gaddam S, Mitsias PD. Periictal diffusion abnormalities of the thalamus in partial status epilepticus. *Epilepsia* 2009;50:265–275.

Jennifer Bestard, MD  
Zaeem A. Siddiqi, MD,  
PhD

### CRYPTOCOCCAL MENINGOENCEPHALITIS IN IMMUNOCOMPETENT PATIENTS: CHANGING TRENDS IN CANADA

Cryptococcosis can range from asymptomatic pulmonary colonization to life-threatening meningitis and disseminated disease. Most infections occur in immunodeficiency states, though recent reports suggest that immunocompetent individuals may be at risk with some varieties of the yeast. *Cryptococcus neoformans var grubii* and *Cryptococcus neoformans var neoformans* infect immunocompromised individuals,<sup>1</sup> whereas *Cryptococcus neoformans var gattii* occurs predominantly in immunocompetent patients and has a strong male preponderance. This variety is found in the tropics in the decaying heartwood of a number of tree species and the outbreak in 2002 on Vancouver Island suggests this region to be the primary ecologic niche of the organism in Canada.<sup>2</sup> To date, no cases of *C neoformans var gattii* in immunocompetent patients have been reported outside British Columbia. We describe clinical features of 3 such patients from Edmonton, Alberta.

**Case reports.** *Case 1.* A 52-year-old previously healthy man presented with a 2-day history of fever, drowsiness, and neck stiffness. In the previous month, he had experienced new onset headaches, excessive daytime sleepiness, decreased mobility, and occasional disorientation, though routine investigations, including brain CT scan, had been normal. His family had moved from British Columbia in 2006. His HIV serology and chest X-ray were normal. CSF had lymphocytic pleocytosis. Brain CT showed hypodensities in basal ganglia, which appeared as multiple septated cysts (cryptococcoma) on MRI with no enhancement or surrounding edema (figure, A–F). CSF India ink stain was positive for cryptococcus and cultures grew *C neoformans var gattii*. Induction therapy with amphotericin B and flucytosine was instituted with daily lumbar punctures for raised intracranial pressure. Subsequently, fluconazole was initiated for 2 weeks followed by maintenance dose for 6 weeks. His condition im-

proved substantially. A month later, he became febrile and had a generalized seizure. CSF opening pressure and cryptococcal antigen titers were elevated and brain MRI revealed ruptured cryptococcoma. Despite aggressive therapy, the patient worsened and died.

*Case 2.* A 59-year-old woman presented with chills, confusion, nausea, dizziness, vertigo, headache, and word-finding difficulties. She had been admitted with a TIA-like episode 2 weeks previously and brain CT/MRI and bloodwork results were normal. She had traveled to Niagara, China, and to Pender Island in British Columbia during the last year. She was afebrile and mildly aphasic. Repeat brain CT and MRI and routine blood studies were normal. CSF had elevated protein (1.7 g/L), reduced glucose, and lymphocytic pleocytosis (108 cells/ $\mu$ L) with elevated cryptococcal antigen titer (1/1024). CSF culture grew *C neoformans var gattii*. With aggressive induction and maintenance therapies, her condition improved rapidly to baseline.

*Case 3.* A 54-year-old man developed confusion and fever suddenly while on a sabbatical in Germany. He had visited his brother in Nanaimo, British Columbia, 3 months previously. CSF and serum antigen titers were positive for cryptococcal antigens. Brain MRI demonstrated diffuse meningoencephalitis (figure, G and H). He was transferred to Edmonton and rapidly improved after initiation of induction therapy (amphotericin B and flucytosine) followed by maintenance therapy with fluconazole.

**Discussion.** Our cases demonstrate some of the challenges in managing cryptococcosis in immunocompetent hosts. Variable clinical manifestations mandate clinicians to have a high suspicion in patients with subacute meningitis and CSF lymphocytic pleocytosis. Travel history is critical. Meningoencephalitis is the most common neurologic manifestation of cryptococcosis and headache the most frequent symptom (>75%). Other symptoms include nausea and vomiting, lethargy, memory loss, personality change, stupor, and coma.<sup>3</sup> Cryptococcoma can cause raised intracranial pressure (50%),

## JUVENILE-ONSET ALPERS SYNDROME: INTERPRETING MRI FINDINGS

N.A. Visser, K.P.J. Braun, W.M. van den Bergh, F.S.S. Leijten, C.R.B. Willems, L.

Ramos, B.J.C. van den Bosch, H.J.M. Smeets and J.H.J. Wokke

*Neurology* 2010;74;1231-1233

DOI: 10.1212/WNL.0b013e3181d90005

**This information is current as of May 7, 2010**

<b>Updated Information &amp; Services</b>	including high-resolution figures, can be found at: <a href="http://www.neurology.org/cgi/content/full/74/15/1231">http://www.neurology.org/cgi/content/full/74/15/1231</a>
<b>Subspecialty Collections</b>	This article, along with others on similar topics, appears in the following collection(s): <b>MRI</b> <a href="http://www.neurology.org/cgi/collection/mri">http://www.neurology.org/cgi/collection/mri</a> <b>DWI</b> <a href="http://www.neurology.org/cgi/collection/dwi">http://www.neurology.org/cgi/collection/dwi</a> <b>Adolescence</b> <a href="http://www.neurology.org/cgi/collection/adolescence">http://www.neurology.org/cgi/collection/adolescence</a> <b>Status epilepticus</b> <a href="http://www.neurology.org/cgi/collection/status_epilepticus">http://www.neurology.org/cgi/collection/status_epilepticus</a> <b>All Genetics</b> <a href="http://www.neurology.org/cgi/collection/all_genetics">http://www.neurology.org/cgi/collection/all_genetics</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/misc/Permissions.shtml">http://www.neurology.org/misc/Permissions.shtml</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://www.neurology.org/misc/reprints.shtml">http://www.neurology.org/misc/reprints.shtml</a>

